BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37709624)

  • 1. Epidemiology of cholangiocarcinoma.
    Qurashi M; Vithayathil M; Khan SA
    Eur J Surg Oncol; 2023 Sep; ():107064. PubMed ID: 37709624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
    Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
    Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
    Xu L; Wang P; Zhang W; Li W; Liu T; Che X
    Front Oncol; 2021; 11():757498. PubMed ID: 34660327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
    Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
    J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.
    Javle M; Lee S; Azad NS; Borad MJ; Kate Kelley R; Sivaraman S; Teschemaker A; Chopra I; Janjan N; Parasuraman S; Bekaii-Saab TS
    Oncologist; 2022 Oct; 27(10):874-883. PubMed ID: 35972334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
    Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
    Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
    Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S
    Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical characteristics and mortality risk between patients with cholangiocarcinoma: A retrospective cohort study.
    Liu Y; Wang Y; Yu Y; Luo H; Zhen M; Ren J
    Front Surg; 2022; 9():1037310. PubMed ID: 36873806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Targeted Therapies for Advanced Cholangiocarcinoma.
    Rizzo A; Brandi G
    Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New epidemiologic trends in cholangiocarcinoma.
    Pascale A; Rosmorduc O; Duclos-Vallée JC
    Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102223. PubMed ID: 37797807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.
    Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S
    J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
    Izquierdo-Sanchez L; Lamarca A; La Casta A; Buettner S; Utpatel K; Klümpen HJ; Adeva J; Vogel A; Lleo A; Fabris L; Ponz-Sarvise M; Brustia R; Cardinale V; Braconi C; Vidili G; Jamieson NB; Macias RI; Jonas JP; Marzioni M; Hołówko W; Folseraas T; Kupčinskas J; Sparchez Z; Krawczyk M; Krupa Ł; Scripcariu V; Grazi GL; Landa-Magdalena A; Ijzermans JN; Evert K; Erdmann JI; López-López F; Saborowski A; Scheiter A; Santos-Laso A; Carpino G; Andersen JB; Marin JJ; Alvaro D; Bujanda L; Forner A; Valle JW; Koerkamp BG; Banales JM
    J Hepatol; 2022 May; 76(5):1109-1121. PubMed ID: 35167909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification.
    Tawarungruang C; Khuntikeo N; Chamadol N; Laopaiboon V; Thuanman J; Thinkhamrop K; Kelly M; Thinkhamrop B
    BMC Cancer; 2021 May; 21(1):497. PubMed ID: 33941120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapies for Perihilar Cholangiocarcinoma.
    Gray S; Lamarca A; Edeline J; Klümpen HJ; Hubner RA; McNamara MG; Valle JW
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell of origin in biliary tract cancers and clinical implications.
    Moeini A; Haber PK; Sia D
    JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology.
    Gringeri E; Gambato M; Sapisochin G; Ivanics T; Lynch EN; Mescoli C; Burra P; Cillo U; Russo FP
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32380750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
    Yousaf A; Kim JU; Eliahoo J; Taylor-Robinson SD; Khan SA
    J Clin Exp Hepatol; 2019; 9(6):740-748. PubMed ID: 31889756
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.